NextCure, Inc. Stock price

Equities

NXTC

US65343E1082

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.23 USD +15.25% Intraday chart for NextCure, Inc. +32.74% +95.61%
Sales 2024 * - Sales 2025 * - Capitalization 62.22M
Net income 2024 * -46M Net income 2025 * -50M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-1.34 x
P/E ratio 2025 *
-1.32 x
Employees 82
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.12%
More Fundamentals * Assessed data
Dynamic Chart
NextCure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Markets on Hold -2- DJ
Top Premarket Decliners MT
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders CI
Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury CI
Nextcure, Inc. Provides Year-End Clinical Pipeline Updates CI
NextCure, Inc. Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML CI
NextCure, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
NextCure, Inc. Announces Presentation of New Preclinical Data Demonstrate Treatment with NC605 CI
NextCure Says Preclinical Data of NC181 for Alzheimer's Disease Shows Amyloid Clearance MT
NextCure, Inc. Presents Preclinical Data on Nc181, A Novel Therapeutic Candidate Targeting Apoe4, for the Treatment of Alzheimer's Disease CI
NextCure, Inc.(NasdaqGS:NXTC) dropped from S&P Global BMI Index CI
NextCure Reports Preclinical Data Show Potential NC605 Application in Bone Disease Treatment MT
HC Wainwright Initiates NextCure With Buy Rating, $7 Price Target MT
NextCure, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news
1 day+15.25%
1 week+32.74%
Current month+28.90%
1 month+39.38%
3 months+93.91%
6 months+72.87%
Current year+95.61%
More quotes
1 week
1.70
Extreme 1.7
2.28
1 month
1.37
Extreme 1.37
2.28
Current year
1.12
Extreme 1.12
2.28
1 year
0.98
Extreme 0.98
2.28
3 years
0.98
Extreme 0.98
10.48
5 years
0.98
Extreme 0.98
109.00
10 years
0.98
Extreme 0.98
109.00
More quotes
Managers TitleAgeSince
Founder 63 15-11-30
Director of Finance/CFO 61 17-12-31
Chief Tech/Sci/R&D Officer 71 21-01-13
Members of the board TitleAgeSince
Chairman 76 15-11-30
Founder 63 15-11-30
Director/Board Member 48 15-11-30
More insiders
Date Price Change Volume
24-03-28 2.23 +15.25% 1,018,516
24-03-27 1.935 -1.78% 112,790
24-03-26 1.97 -1.01% 301,294
24-03-25 1.99 +4.74% 377,792
24-03-22 1.9 +13.10% 1,019,015

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.23 USD
Average target price
5 USD
Spread / Average Target
+124.22%
Consensus
  1. Stock
  2. Equities
  3. Stock NextCure, Inc. - Nasdaq